Illumina, Inc. (ILMN)
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Illumina (ILMN): Bullish Structure Builds After Breakout
Illumina maintains a long-term bullish reversal after breaking out of an inverse head and shoulders pattern, with key support holding as upside targets remain in focus.
ILMN Stock Jumps 98.7% in a Year: What's Powering the Surge?
Illumina shares surge 98.7% in a year as NovaSeq X adoption accelerates, clinical sequencing demand grows, and the company tops Q1 2026 guidance.
Here's Why Illumina (ILMN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is This the Right Time to Retain ILMN Stock in Your Portfolio?
Illumina advances its sequencing strategy with strong NovaSeq X momentum and clinical demand, but China's weakness and macro pressures cloud the outlook.
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Illumina (ILMN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Illumina, Inc. (ILMN) Q1 2026 Earnings Call Transcript
Illumina, Inc. (ILMN) Q1 2026 Earnings Call Transcript
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates
Illumina (ILMN) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $0.97 per share a year ago.
Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now?
TEM and ILMN battle in precision oncology, but stronger stock gains, valuation and earnings outlook position ILMN as the more compelling pick now.
